GeoVax Labs, Inc. has completed required release testing for clinical supplies of its GEO-MVA vaccine candidate for protection against mpox and smallpox, with final product release scheduled for early April. This milestone advances the program toward initiation of a planned immune bridging study in the second half of this year, a critical step toward potential regulatory approval under the European Medicines Agency's expedited development pathway.
The availability of GEO-MVA clinical material marks significant progress for the program, according to David Dodd, Chairman and Chief Executive Officer of GeoVax. "With final product release expected shortly, we are entering the final preparatory phase ahead of initiating our immune bridging study positioning GeoVax at a pivotal inflection point, moving toward potential regulatory approval and subsequent commercialization," Dodd stated.
The planned immune bridging study is designed to demonstrate comparability to an approved Modified Vaccinia Ankara (MVA) vaccine using immunological endpoints, consistent with EMA guidance supporting a streamlined development pathway. This approach could enable regulatory approval based on a single study demonstrating non-inferiority to an approved MVA vaccine.
GeoVax has initiated outreach discussions with organizations that influence or directly procure vaccines for national stockpiles, military preparedness programs, and international outbreak response initiatives. These discussions, detailed in recent announcements available at https://www.geovax.com, position the company for rapid vaccine distribution upon regulatory approval or Emergency Use Licensing issuance.
"We are encouraged by the early engagement with global health and preparedness stakeholders," Dodd added. "These discussions, alongside our clinical progress, underscore the increasing recognition of the critical need to expand global supply of MVA-based vaccines."
GEO-MVA is being developed to address a significant gap in global vaccine preparedness. Recent mpox outbreaks and evolving epidemiological patterns have reinforced the need for sustained preparedness, including expanded manufacturing capacity and diversified supply sources. The current supply of MVA vaccine is concentrated with a single commercial manufacturer, limiting redundancy in a platform considered essential for protection against both mpox and smallpox.
GeoVax believes GEO-MVA has the potential to serve as an important additional source of MVA vaccine supply supporting national stockpile programs, global outbreak response efforts, and military and biodefense preparedness initiatives. The program's advancement comes as global health authorities seek to diversify vaccine supply chains and enhance preparedness for orthopoxvirus threats.
The company's progress represents a strategic step toward addressing vulnerabilities in global health security infrastructure. By potentially providing an alternative MVA vaccine source, GeoVax could contribute to more resilient pandemic preparedness systems and reduce dependence on single suppliers for critical medical countermeasures.
